Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Vertex Pharmaceuticals Inc. stock rises Thursday, still underperforms market
Vertex Pharmaceuticals Inc. closed $47.49 short of its 52-week high ($510.64), which the company reached on August 1st.
Vertex Pharmaceuticals Incorporated (VRTX) Stock: Surpassing Expectations in the Market?
Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $462.99 which represents a slight increase of $2.99 or 0.65% from the prior close of $460. The stock opened at $459.
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.65% higher to $462.99 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500
19h
Vertex Says Health Canada Accepts NDS For Triple Combination To Treat Cystic Fibrosis
Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) announced Thursday that Health Canada has accepted for review its New Drug ...
1d
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an ...
MedCity News
3d
Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis
Vertex
Pharmaceuticals
’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today,
Vertex
’s portfolio of blockbuster CF products spans ...
FiercePharma
2d
Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy
With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...
18h
bluebird bio: Scientific Success And Financial Success, And The Gap Between
Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...
1d
Health Canada Oks Vertex's CASGEVY, First CRISPR/Cas9 Gene-Edited Therapy For Sickle Cell Disease
Vertex Pharmaceuticals Inc. (VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene ...
BioSpace
9d
Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...
7d
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...
U.S. News & World Report
2d
Vertex Pharmaceuticals, Inc.
U.S.
News
' panel of financial advisors addresses the No. 1 issue on investors' minds in the back half of 2024.
Zacks.com on MSN
21h
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
S&P 500 Index
Casgevy
Health Canada
Lonza Group
Feedback